SHBG (Extended) Medication-Driven Changes: What Every Patient and Clinician Should Know

Sex hormone-binding globulin (SHBG) is a liver-made protein that binds testosterone and estradiol in blood, leaving only a small unbound fraction free to act on tissue. The "extended" SHBG panel reports the SHBG concentration itself (in nmol/L) plus a calculated free testosterone and calculated bioavailable testosterone, usually derived from the Vermeulen equation using total testosterone, SHBG, and an assumed or measured albumin. This is a laboratory panel, not a drug, so there is no FDA-approved indication to discuss; what matters clinically is that many common medications shift SHBG enough to change the calculated numbers even when total testosterone or estradiol hasn't moved.

The core point worth remembering: SHBG is not a fixed baseline trait, it is a hepatic protein whose synthesis responds to hormones, thyroid status, and insulin, which means a "new" abnormal free testosterone or free estradiol result is often explained by a medication change rather than a change in gonadal function. Oral estrogen-containing products (combined oral contraceptives, oral menopausal or feminizing hormone therapy) are the most reliable drivers of SHBG elevation because they reach the liver in first pass; exogenous androgens (testosterone therapy, danazol, stanozolol) are the most reliable drivers of SHBG suppression. Everything else on this page sits between those two anchors in strength of effect and quality of evidence.

What the extended panel adds and why route of administration matters

Testosterone circulates in three fractions: a majority bound tightly to SHBG, a substantial minority loosely bound to albumin, and a small free fraction. Only the free and albumin-bound fractions are considered biologically available. When SHBG rises, total testosterone can look normal while calculated free testosterone falls into a range consistent with androgen deficiency. When SHBG falls, calculated free testosterone rises even if total testosterone is flat. This is the entire rationale for ordering the extended panel instead of total testosterone alone, and it is also why a medication history has to accompany every result.

The Vermeulen equation, which most reference labs use to generate the calculated free testosterone value, was validated against equilibrium dialysis and performs reasonably well in typical outpatient settings. It becomes less reliable when serum albumin is abnormal, for example in advanced liver disease, nephrotic syndrome, or severe illness, because the equation assumes a standard albumin value unless a measured albumin is entered. Clinicians should request a measured albumin in those situations rather than rely on the assumed value.

Medications and conditions that raise SHBG

Oral estrogens, including combined oral contraceptives

Oral estrogens are the strongest and most consistently reported driver of SHBG elevation in the endocrinology literature. Ethinyl estradiol and oral estradiol both undergo first-pass hepatic metabolism and stimulate SHBG gene transcription directly; this is a well-established, mechanistically understood effect, not a marginal finding. Combined oral contraceptives commonly raise SHBG several-fold above an individual's baseline within a few cycles, and the specific progestin in the pill modulates how large that rise is (androgenic progestins such as levonorgestrel blunt it somewhat, anti-androgenic progestins such as drospirenone or cyproterone acetate allow it to go higher). This SHBG rise, and the resulting fall in free androgen index, is the accepted mechanism behind using combined oral contraceptives to treat androgen-driven acne and hirsutism in polycystic ovary syndrome, a use reflected in Endocrine Society PCOS management guidance.

A clinically important detail is that SHBG does not necessarily normalize the moment a patient stops the pill. Elevated SHBG, and therefore suppressed free testosterone, can persist for a period of months after discontinuation in some patients. Any SHBG-extended panel drawn within roughly six months of stopping a combined oral contraceptive should be interpreted with that history in mind rather than assumed to reflect a stable, medication-free baseline. The exact duration of this "washout" effect varies by study and should be confirmed against the primary literature rather than treated as a fixed number.

Oral versus transdermal estrogen in menopausal and feminizing hormone therapy

Oral estradiol and conjugated equine estrogen both raise SHBG through the same first-pass hepatic mechanism as oral contraceptives. Transdermal estradiol largely bypasses first-pass hepatic metabolism and produces a much smaller SHBG change at an equivalent estrogenic dose. This route-dependent difference is well described in the menopausal hormone therapy literature and is the reason a clinician reading an SHBG-extended panel in a patient on hormone therapy needs to record the route of administration, not only the hormone and dose. The same logic applies to transgender women on oral estradiol, where SHBG elevation contributes to suppression of free testosterone alongside anti-androgen therapy. WPATH's Standards of Care recommend following total testosterone, free testosterone, and estradiol together in this population, with SHBG treated as context for interpreting those numbers rather than a treatment target in itself.

Thyroid hormone and hyperthyroid states

Thyroid hormone stimulates hepatic SHBG production, and hyperthyroidism (whether from disease or from over-replacement with levothyroxine) is associated with elevated SHBG; hypothyroidism is associated with lower SHBG. In practice, a patient on levothyroxine with a suppressed TSH can have an SHBG elevation that partly mimics the pattern seen with oral estrogen use. Checking TSH before attributing an elevated SHBG to another medication, or before concluding that low free testosterone reflects a hormonal deficiency, is a reasonable and low-cost step.

Weight loss and GLP-1/GIP receptor agonists

Obesity is associated with hyperinsulinemia, and insulin suppresses hepatic SHBG synthesis through an insulin response element on the SHBG gene promoter. Substantial weight loss, by lowering insulin levels, tends to raise SHBG. Semaglutide and tirzepatide are FDA-approved for chronic weight management and produce weight loss large enough, in their pivotal trials, to plausibly drive this mechanism. Small observational studies in women with PCOS have reported meaningful SHBG increases alongside semaglutide-driven weight loss and improved menstrual regularity, which is biologically consistent with the insulin mechanism, but the specific magnitude reported in any single small study should be verified against the primary paper before being quoted as an expected effect size for an individual patient. Comparable SHBG effects would be expected mechanistically with tirzepatide given its larger average weight loss, though dedicated SHBG outcome data from its pivotal obesity trials were not confirmed for this article and should be checked before being stated as established.

Practical implication: a patient on stable testosterone replacement therapy who starts a GLP-1 or GIP/GLP-1 agonist and loses a clinically significant amount of weight may see SHBG rise enough to lower calculated free testosterone even though the TRT dose and total testosterone are unchanged. That pattern can reproduce hypogonadal symptoms without any change in the testosterone prescription, and the SHBG-extended panel, not total testosterone alone, is the tool that will show it.

Insulin-sensitizing medications

Because insulin suppresses SHBG synthesis, drugs that lower circulating insulin or improve insulin sensitivity tend to raise SHBG. Metformin has been reported to produce a modest SHBG increase in women with PCOS across pooled trial data, smaller in magnitude than the effect of oral estrogen or of thiazolidinediones such as pioglitazone. The exact pooled effect size and the specific pioglitazone trial data referenced in earlier versions of this article could not be independently confirmed here and should be verified against the primary trial reports before being cited to a patient as a precise number.

Growth hormone therapy

Recombinant growth hormone therapy raises SHBG, plausibly through increased hepatic IGF-1 production stimulating SHBG synthesis, and adult growth hormone deficiency is associated with low SHBG that rises toward normal with replacement. This is a smaller, more specialized population than the other categories above and is mentioned here mainly so it is not mistaken for an unexplained SHBG change in a patient on GH therapy for a pituitary condition.

Medications that lower SHBG

Testosterone replacement therapy and other exogenous androgens

Exogenous testosterone suppresses SHBG, most likely through androgen receptor-mediated inhibition of hepatic SHBG gene transcription combined with suppression of endogenous LH-driven testosterone production. In men starting testosterone replacement therapy, SHBG typically declines over the first several months of stable dosing. Because total testosterone rises at the same time SHBG falls, the combined effect on calculated free testosterone is larger than either change alone would suggest. This is the main reason clinicians monitoring TRT should recheck the full SHBG-extended panel, not total testosterone in isolation, after any dose change, and should allow enough time (commonly several weeks) at a stable dose before interpreting the recheck.

Danazol, stanozolol, and other 17-alpha alkylated androgens

Oral 17-alpha alkylated androgens, including danazol (used for endometriosis and hereditary angioedema) and stanozolol, are reported to suppress SHBG more aggressively than injectable testosterone, in some study populations by roughly half. These are older and smaller studies; the precise percentage suppression for a given dose should be verified against the primary literature rather than applied as a fixed rule for an individual patient.

DHEA supplementation

Over-the-counter dehydroepiandrosterone (DHEA) has been reported to modestly lower SHBG in postmenopausal women, with a correspondingly small rise in free testosterone and free estradiol. The effect appears smaller than that of prescription androgens, but because DHEA is available without a prescription, patients frequently do not volunteer that they are taking it. Asking specifically about DHEA and other over-the-counter hormone supplements before interpreting an SHBG-extended panel is worthwhile.

Glucocorticoids

Oral glucocorticoids have been reported to modestly suppress SHBG, through suppression of hepatic SHBG gene transcription. In a patient on chronic corticosteroid therapy, a lower SHBG could overestimate calculated free testosterone relative to what a gold-standard measurement (such as equilibrium dialysis) would show.

Enzyme-inducing anti-epileptic drugs work the opposite direction

Enzyme-inducing anti-epileptic drugs (phenytoin, carbamazepine, phenobarbital) induce hepatic cytochrome P450 activity and are reported to raise SHBG, which lowers free testosterone and free estradiol; valproate, a non-enzyme-inducing agent, does not share this effect and may weakly lower SHBG. This is listed here as a raising factor for clarity, since it is easy to assume all anti-epileptics behave the same way.

Is there an "optimal" SHBG range?

No single universal optimal SHBG value exists, because the right context depends on sex, life stage, and what medications a person is taking. What can be said with more confidence:

• Adult male reference ranges commonly cited by major reference laboratories fall in the range of roughly 10 to 60 nmol/L, and the Endocrine Society's testosterone therapy guideline discusses interpreting free testosterone in the context of SHBG abnormalities rather than fixing a single ideal SHBG number.
• Very low SHBG in men (well below the reference range) is associated with disproportionately high free testosterone at a given total testosterone level and, anecdotally in clinical practice, with higher erythrocytosis risk on TRT; this pattern is plausible and widely discussed but should not be treated as a precisely quantified risk threshold without checking current guideline text.
• Premenopausal women not on hormonal contraception typically run higher than men, and women with PCOS often run lower than typical premenopausal values, consistent with the hyperinsulinemia and androgen excess seen in PCOS.
• Women on combined oral contraceptives routinely run above the "normal" premenopausal range, which is the expected pharmacologic effect described above, not a sign of pathology.
• Transgender women on oral estrogen and transgender men on testosterone will show SHBG values shifted in the expected direction for their regimen; WPATH's Standards of Care frame this as context for interpreting testosterone and estradiol values rather than a target in itself.

The Endocrine Society, the Menopause Society (NAMS), and WPATH have each published guidance touching on how SHBG should be considered when interpreting testosterone or estradiol results in their respective populations. Because this draft could not independently verify exact wording from those documents, direct quotations have been removed; anyone citing specific guideline language should pull it from the current published guideline rather than from this article.

Timing a blood draw around medications

For men on injectable testosterone (cypionate or enanthate), SHBG and calculated free testosterone vary across the injection interval, generally lowest shortly after injection and highest just before the next dose. Drawing at trough, immediately before the next scheduled injection, gives the most comparable result across visits.

For most oral medications, a single day's dose does not meaningfully move SHBG on its own, so draw timing relative to a daily pill is not critical. What matters more is steady state: for medications that chronically raise or lower SHBG (oral contraceptives, TRT, levothyroxine, GLP-1 agonists), allow enough time on a stable dose, commonly six to eight weeks at minimum, before treating a result as representative of that medication's steady-state effect.

Decision framework: is this SHBG change explained by a medication, or does it need further workup?

Use this sequence when a free testosterone, free estradiol, or SHBG value looks unexpected compared with a prior result.

Step 1: Confirm nothing changed in the assay or draw conditions. Same lab, same time relative to last injection (if applicable), fasting status similar to prior draw. If the draw timing changed (for example, drawn at peak instead of trough for injectable testosterone), repeat the test under matched conditions before concluding anything changed biologically.

Step 2: Take a complete medication and supplement history, including anything started or stopped in the last six months. Ask specifically about: oral estrogen or combined oral contraceptives (including recent discontinuation), any testosterone or other androgen product, DHEA or other over-the-counter hormone supplements, GLP-1/GIP agonists and recent weight change, thyroid medication and most recent TSH, enzyme-inducing anti-epileptic drugs, oral glucocorticoids, and growth hormone therapy.

Step 3: Check direction of change against the expected mechanism.

Step 4: Decide whether the calculated free testosterone or free estradiol, not just SHBG, should drive the clinical decision. If a medication explains the SHBG shift and the patient is asymptomatic, it is usually reasonable to interpret the calculated free hormone value in that context rather than adjust a hormone therapy dose. If the patient has new symptoms (new hypogonadal symptoms on stable TRT, new virilization on stable estrogen therapy, unexplained erythrocytosis), the medication explanation for the SHBG shift does not remove the need to evaluate and, if appropriate, adjust the hormone dose. SHBG interpretation clarifies why a number moved; it does not substitute for treating the patient's symptoms.

Step 5: Escalate rather than reassure when any of the following are present. Signs of erythrocytosis (very high hematocrit) in a patient on TRT, new symptoms of thyrotoxicosis, unexplained rapid weight change, or any SHBG/free-hormone pattern that does not track with a known medication explanation. These situations warrant a full clinical evaluation rather than lab-only reassurance.

What is established, what is plausible, and what is not established

Established: SHBG is a hepatically synthesized protein that binds testosterone and estradiol; oral (first-pass) estrogen reliably raises SHBG; exogenous androgens reliably lower SHBG; insulin suppresses hepatic SHBG synthesis, so states of hyperinsulinemia (obesity, PCOS) are associated with lower SHBG and its reversal (weight loss, insulin sensitizers) with higher SHBG; the calculated free testosterone value is directly dependent on the SHBG value used in the equation.

Plausible but not precisely quantified here: the exact percentage change in SHBG produced by a specific drug, dose, or duration (for example, the precise magnitude of SHBG suppression with a given TRT dose, or the precise SHBG rise with a given amount of GLP-1-driven weight loss). These effects are directionally well supported but the specific numbers circulating in secondary sources vary by study population and should be checked against the primary trial or cohort report before being used to counsel an individual patient.

Not established from the material available for this article: a single universal "optimal" SHBG target for men or women on hormone therapy; a precise duration for how long SHBG stays elevated after stopping combined oral contraceptives in a given patient; a confirmed SHBG effect size for tirzepatide from its pivotal obesity trials.

Practical checklist before interpreting an SHBG-extended result

• Record the route of any estrogen exposure (oral versus transdermal); this changes the expected SHBG effect substantially.
• Record all androgen-containing products, including DHEA and other over-the-counter supplements.
• Record GLP-1/GIP agonist use and any recent weight change of more than about 5% of body weight.
• Check TSH; unstable thyroid status can confound the interpretation.
• Note use of enzyme-inducing anti-epileptic drugs or chronic oral glucocorticoids.
• For injectable testosterone, draw at trough (just before the next injection) for a comparable result across visits.
• For patients who recently stopped an oral contraceptive, note the interval since the last pill; SHBG may still be elevated for a period of months.
• Request a measured albumin, rather than relying on the assumed value, if the patient has liver disease, nephrotic syndrome, or severe illness, since this affects the accuracy of the calculated free testosterone.

A note on the evidence behind this page

The mechanisms described above (first-pass hepatic estrogen effects, androgen suppression of hepatic SHBG transcription, insulin suppression of SHBG synthesis) are well established in the endocrinology literature and reflected in major guideline discussions from bodies such as the Endocrine Society, the Menopause Society, and WPATH. The specific numeric effect sizes attributed to individual drugs, doses, or small studies in earlier drafts of this article could not be independently verified against a confirmed primary source for this revision and have been described qualitatively or removed rather than presented as fixed figures. Anyone using this page to counsel a specific patient should confirm any precise percentage or study result against the current primary literature (searchable at pubmed.ncbi.nlm.nih.gov) or the current text of the relevant guideline before relying on it for an individual dosing or interpretation decision. This article does not provide individualized dosing or diagnosis and is not a substitute for review by the prescribing clinician.